Reviva Pharmaceuticals Holdings Inc (RVPHW) - Total Assets
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc (RVPHW) holds total assets worth $14.33 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Reviva Pharmaceuticals Holdings Inc net assets for net asset value and shareholders' equity analysis.
Reviva Pharmaceuticals Holdings Inc - Total Assets Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc's total assets have evolved over time, based on quarterly financial data.
Reviva Pharmaceuticals Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Reviva Pharmaceuticals Holdings Inc's total assets of $14.33 Million consist of 94.7% current assets and 5.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RVPHW company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Reviva Pharmaceuticals Holdings Inc's current assets represent 94.7% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 86.9% of total assets in 2024, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Reviva Pharmaceuticals Holdings Inc Competitors by Total Assets
Key competitors of Reviva Pharmaceuticals Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Reviva Pharmaceuticals Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 0.39 | 6.57 |
| Quick Ratio | 1.39 | 0.39 | 6.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.77 Million | $-10.72 Million | $7.43 Million |
Reviva Pharmaceuticals Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Reviva Pharmaceuticals Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -34.6% |
| Total Assets | $15.50 Million |
| Market Capitalization | $28.53 USD |
Valuation Analysis
Below Book Valuation: The market values Reviva Pharmaceuticals Holdings Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Reviva Pharmaceuticals Holdings Inc's assets decreased by 34.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Reviva Pharmaceuticals Holdings Inc (2018–2024)
The table below shows the annual total assets of Reviva Pharmaceuticals Holdings Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $15.50 Million | -34.59% |
| 2023-12-31 | $23.70 Million | +25.24% |
| 2022-12-31 | $18.92 Million | -39.74% |
| 2021-12-31 | $31.40 Million | +258.40% |
| 2020-12-31 | $8.76 Million | +336910.69% |
| 2019-12-31 | $2.60K | -100.00% |
| 2018-12-31 | $65.24 Million | -- |
About Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more